{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T17:48:33Z","timestamp":1775324913394,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Experimental Eye Research"],"published-print":{"date-parts":[[2005,3]]},"DOI":"10.1016\/j.exer.2004.10.009","type":"journal-article","created":{"date-parts":[[2004,12,15]],"date-time":"2004-12-15T01:51:40Z","timestamp":1103075500000},"page":"435-442","source":"Crossref","is-referenced-by-count":51,"title":["Inhibition of corneal neovascularization by a peroxisome proliferator-activated receptor-\u03b3 ligand"],"prefix":"10.1016","volume":"80","author":[{"given":"Melvin A.","family":"Sarayba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tulaya","family":"Tungsiripat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norman H.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula M.","family":"Sweet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anup J.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn E.","family":"Osann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amar","family":"Chittiboyina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen C.","family":"Benson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harrihar A.","family":"Pershadsingh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roy S.","family":"Chuck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.exer.2004.10.009_bib1","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1167\/iovs.02-1060","article-title":"Role of PPAR-\u03b3 ligand in neuroportection against glutamate-induced cytotoxicity in retinal ganglion cells","volume":"44","author":"Aoun","year":"2003","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2004.10.009_bib2","first-page":"274","article-title":"Corneal neovascularization induced by xenografts or chemical cautery. Inhibition by cyclosporin A","volume":"38","author":"Benelli","year":"1997","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2004.10.009_bib3","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0895-7061(99)00148-X","article-title":"Peroxisome proliferator-activated receptor (PPAR) gamma expression in human vascular smooth muscle cells: inhibition of growth, migration, and c-fos expression by the PPAR-gamma activator troglitazone","volume":"13","author":"Benson","year":"2000","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.exer.2004.10.009_bib4","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S0014-5793(01)02614-X","article-title":"15-Deoxy-\u03942,14-PGJ2, but not troglitazone, modulates IL-1\u03b2 effects in human chondrocytes by inhibiting NF-\u03baB and AP-1 activation pathways","volume":"501","author":"Boyault","year":"2001","journal-title":"FEBS Lett."},{"key":"10.1016\/j.exer.2004.10.009_bib5","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/00055735-200108000-00002","article-title":"Corneal neovascularization","volume":"12","author":"Chang","year":"2001","journal-title":"Curr. Opin. Ophthalmol."},{"key":"10.1016\/j.exer.2004.10.009_bib6","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s001090000145","article-title":"The pleiotropic functions of peroxisome proliferator-activated receptor-gamma","volume":"79","author":"Debril","year":"2001","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.exer.2004.10.009_bib7","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1677\/joe.0.1690453","article-title":"Peroxisome proliferator-activated receptors in inflammation control","volume":"169","author":"Delerive","year":"2001","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.exer.2004.10.009_bib8","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1001\/archderm.136.5.609","article-title":"Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-\u03b3 inhibit keratinocyte proliferation","volume":"136","author":"Ellis","year":"2000","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.exer.2004.10.009_bib9","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1210\/jc.86.3.1306","article-title":"Suppression of nuclear factor-\u03baB and stimulation of inhibitor-\u03baB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese","volume":"86","author":"Ghanim","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.exer.2004.10.009_bib10","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1677\/joe.0.1690461","article-title":"Potential roles of the peroxisome proliferator-activated receptor-\u03b3 in macrophage biology and atherosclerosis","volume":"169","author":"Glass","year":"2001","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.exer.2004.10.009_bib11","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1006\/bbrc.2000.3084","article-title":"The effects of thiazolidinediones on vascular smooth muscle cell activation by angiotensin II","volume":"273","author":"Hattori","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.exer.2004.10.009_bib12","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/35154","article-title":"PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines","volume":"391","author":"Jiang","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.exer.2004.10.009_bib13","first-page":"1625","article-title":"A model of angiogenesis in the mouse cornea","volume":"37","author":"Kenyon","year":"1996","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2004.10.009_bib14","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1210\/rp.56.1.239","article-title":"Peroxisome proliferator-activated receptors: from genes to physiology","volume":"56","author":"Kliewer","year":"2001","journal-title":"Recent Prog. Horm. Res."},{"key":"10.1016\/j.exer.2004.10.009_bib15","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s004170050015","article-title":"Inhibition of corneal neovascularization by \u03b1v-integrin antagonists in the rat","volume":"238","author":"Klotz","year":"2000","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.exer.2004.10.009_bib16","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1210\/jc.86.7.3452","article-title":"Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes","volume":"86","author":"Koshiyama","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.exer.2004.10.009_bib17","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1089\/104303401750270959","article-title":"Inhibition of angiogenesis by adenovirus-mediated sFlt-1 expression in a rat model of corneal neovascularization","volume":"12","author":"Lai","year":"2001","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.exer.2004.10.009_bib18","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0039-6257(98)00035-6","article-title":"Ocular neovascularization: an epidemiologic review","volume":"43","author":"Lee","year":"1998","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.exer.2004.10.009_bib19","first-page":"855","article-title":"Transdifferentiated RPE cells and VEGF immunoreactivity in surgically-excised ARMD-related choroidal neovascular membranes","volume":"37","author":"Lopez","year":"1996","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2004.10.009_bib20","doi-asserted-by":"crossref","first-page":"346","DOI":"10.2337\/diabetes.49.3.346","article-title":"Anti-inflammatory actions of 15-deoxy-\u03b312,14-prostaglandin J2 and troglitazone: evidence for heat shock-dependent and -independent inhibition of cytokine-induced inducible nitric oxide synthase expression","volume":"49","author":"Maggi","year":"2000","journal-title":"Diabetes"},{"key":"10.1016\/j.exer.2004.10.009_bib21","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0002-9440(10)65540-X","article-title":"Macrophages in human atheroma contain PPAR\u03b3: differentiation-dependent PPAR\u03b3 expression and reduction of MMP-9 activity through PPAR\u03b3 activation in mononuclear phagocytes in vitro","volume":"153","author":"Marx","year":"1998","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.exer.2004.10.009_bib22","first-page":"2309","article-title":"Peroxisome proliferator-activated receptor-gamma ligands inhibit choroidal neovascularization","volume":"41","author":"Murata","year":"2000","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2004.10.009_bib23","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1001\/archopht.119.5.709","article-title":"Response of experimental retinal neovascularization to thiazolidinediones","volume":"119","author":"Murata","year":"2001","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.exer.2004.10.009_bib24","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1172\/JCI0215634","article-title":"PPAR-gamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis","volume":"110","author":"Panigrahy","year":"2002","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.exer.2004.10.009_bib25","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1517\/13543784.8.11.1859","article-title":"Pharmacological peroxisome proliferator-activated receptor \u03b3 ligands: emerging clinical indications beyond diabetes","volume":"8","author":"Pershadsingh","year":"1999","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.exer.2004.10.009_bib26","series-title":"Ocular diseases and peroxisome proliferator-activated receptor-gamma (PPAR\u03b3) in mammalian eye. Society for Neuroscience, 29th Annual Meeting, Miami Beach, FL","author":"Pershadsingh","year":"1999"},{"key":"10.1016\/j.exer.2004.10.009_bib27","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/34178","article-title":"The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation","volume":"391","author":"Ricote","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.exer.2004.10.009_bib28","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/386671a0","article-title":"Mechanisms of angiogenesis","volume":"386","author":"Risau","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.exer.2004.10.009_bib29","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/med.1006","article-title":"Cyclopentenone prostaglandins: new insights on biological activities and cellular targets","volume":"21","author":"Straus","year":"2001","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.exer.2004.10.009_bib30","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S0016-5085(01)70084-4","article-title":"Antineoplastic and anti-inflammatory effects of PPAR ligands in colitis","volume":"21","author":"Su","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.exer.2004.10.009_bib31","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1076\/ocii.9.1.9.3978","article-title":"The role of cytokines in corneal immunopathology","volume":"9","author":"Torres","year":"2001","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.exer.2004.10.009_bib32","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S1471-4914(01)02076-7","article-title":"PPAR\u03b3 and inflammatory bowel disease: a new therapeutic target for ulcerative colitis and Crohn's disease","volume":"7","author":"Wada","year":"2001","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.exer.2004.10.009_bib33","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1146\/annurev.biochem.70.1.341","article-title":"Peroxisome proliferator-activated receptor-gamma and metabolic disease","volume":"70","author":"Willson","year":"2001","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.exer.2004.10.009_bib34","doi-asserted-by":"crossref","first-page":"9116","DOI":"10.1074\/jbc.274.13.9116","article-title":"Peroxisome proliferator-activated receptor \u03b3 ligands are potent inhibitors of angiogenesis in vitro and in vivo","volume":"74","author":"Xin","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.exer.2004.10.009_bib35","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1074\/jbc.275.7.4541","article-title":"Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPAR\u03b3) agonists. PPAR\u03b3 co-association with transcription factor NFAT","volume":"275","author":"Yang","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.exer.2004.10.009_bib36","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0002-9440(10)61777-4","article-title":"Control of stromal keratitis by inhibition of neovascularization","volume":"159","author":"Zheng","year":"2001","journal-title":"Am. J. Pathol."}],"container-title":["Experimental Eye Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483504003100?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483504003100?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T10:22:38Z","timestamp":1548930158000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014483504003100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["S0014483504003100"],"URL":"https:\/\/doi.org\/10.1016\/j.exer.2004.10.009","relation":{},"ISSN":["0014-4835"],"issn-type":[{"value":"0014-4835","type":"print"}],"subject":[],"published":{"date-parts":[[2005,3]]}}}